Driving Progress in Cardiology: Exploring the Role of FXI in Acute Coronary Syndromes & Beyond
Driving Progress in Cardiology: Exploring the Role of FXI in Acute Coronary Syndromes & Beyond
Source: SCAI 2025 Educational Program
(Driving Progress in Cardiology – FXI in ACS & Beyond )
FXI inhibitors = Factor XI / Factor XIa inhibitors in the coagulation cascade (target the intrinsic pathway to reduce thrombosis with lower bleeding risk).
• FXI inhibition reduces clotting with less bleeding.
• Promising in ACS as an add-on to antiplatelets.
• Potential role also in stroke, AF, and VTE.
Summary :
• Asundexian: Studied in PACIFIC trials (post-MI, AF, stroke).
• Milvexian: Phase 2 (AXIOMATIC-SSP) and Phase 3 LIBREXIA program (stroke, ACS, AF).
• Abelacimab: AZALEA-TIMI 71 (AF), VTE prevention post-arthroplasty.
• Osocimab: Early safety trial in renal disease.
